Dominique Bridon

Optivia Biotechnology, Inc. provides contract research organization offering drug transporter research services and solutions to biotechnology, pharmaceutical and academic organizations. It offers regulatory DDI studies, transporter screening, tranporter profiling, and custom development services. The firm's products include TransFlex Single Transporter Assay Plates,TransFlex Multi-Transporter Model Plates, and Certified Efflux Transporter Vesicles. The company was founded by Yong Huang, Pascal Druzgala and Peter G. Milner in 2007 and is headquartered in Santa Clara, CA.

Diaccurate SASU engages in the research of diagnostic products. It offers diagnostic products especially in the field of theranostics. The firm operates as a biopharmaceutical company that engages in developing new therapies for the treatment of HIV infection. The company was founded in 2012 and is headquartered in Paris, France.

Sibylla Biotech Srl engages in research and development activities in the pharmaceutical sector. It specializes in studies through its proprietary atom computer simulations for new drug discoveries. The company was founded by Maria Letizia Barreca and Emiliano Biasini in 2017 and is headquartered in Trento, Italy.

BlueLight Therapeutics, Inc. develops novel systems to analyze real-time protein function for research and clinical applications. The firm offers technology for detecting conformational change in proteins and other biological molecules. Its technology is based on a phenomenon called second-harmonic generation (SHG), can monitor structural changes at any site within a protein, in real time and since protein function is determined by its structure, and changes in structure cause changes in function, characterizing these changes will provide significant insights into how the body functions and respond to treatments. The company was founded by Joshua S. Salafsky and Greg S. Yap in 2013 and is headquartered in South San Francisco, CA.

NEURONAX SA develops and provides drugs supporting neural repair to treat degenerative disorders of the central nervous system. Its services include cell culture, in vitro evaluation, neurotrophic and neuroprotective effects analysis, culture analyses, and stem cells. The company was founded by Stéphane Gobron, Fabrice Cailloux, and Pierre-Yves Simonin in 2003 and is headquartered in Saint-Beauzire, France.